Aurobindo Pharma Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 12, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1476 as of 12 Jun 11:33 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 8970 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the growth of 1.54% The revenue of Divis Laboratories Ltd for the Mar '26 is ₹ 2986 crore as compare to the Dec '25 revenue of ₹ 2692 crore. This represent the growth of 10.92% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 1867 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -1.51% The ebitda of Divis Laboratories Ltd for the Mar '26 is ₹ 1089 crore as compare to the Dec '25 ebitda of ₹ 904 crore. This represent the growth of 20.46% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 920.84 crore over 8 quarters. This represents a CAGR of 0.14% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 751 crore over 8 quarters. This represents a CAGR of 32.16% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Aurobindo Pharma Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Divis Laboratories Ltd?

Market cap of Aurobindo Pharma Ltd is 85,035 Cr while Market cap of Divis Laboratories Ltd is 176,569 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Divis Laboratories Ltd?

The stock performance of Aurobindo Pharma Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Divis Laboratories Ltd?

As of June 12, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1464.1. On the other hand, Divis Laboratories Ltd stock price is INR ₹6651.25.

How do dividend payouts of Aurobindo Pharma Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.